CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.
äŒæ¥ã³ãŒãCDNA
äŒç€ŸåCareDx Inc
äžå Žæ¥Jul 17, 2014
æé«çµå¶è²¬ä»»è
ãCEOãHanna (John W)
åŸæ¥å¡æ°644
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Jul 17
æ¬ç€Ÿæåšå°8000 Marina Blvd
éœåžBRISBANE
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·94005
é»è©±çªå·14152872300
ãŠã§ããµã€ãhttps://www.caredx.com/
äŒæ¥ã³ãŒãCDNA
äžå Žæ¥Jul 17, 2014
æé«çµå¶è²¬ä»»è
ãCEOãHanna (John W)